A

AVTX

AVTX

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
AVTX Live QuoteReal-time
$6.75
$5.51(-44.94%)1M
Day Range$6.53 – $6.87
Open$6.73
Previous Close$6.70
Volume710.4K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$387.42M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-2.26
Price to Book0.9
Dividend Yield0.65%
Beta (Volatility)0.74
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $6.75 (1%)
Low: $6.53High: $24.27
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$34.80-76.8% upside

Insider Buys

1

$13K

Insider Sales

23

$8.50M

Total Volume

$8.51M

44 transactions

Net Activity

$8.49M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
35CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
S
1

Sullivan Christopher Ryan

CFO

0 buys7 sells

$3.72M total

D
2

Doyle Mittie

Chief Medical Officer

0 buys12 sells

$2.98M total

V
3

Varki Paul

GC

0 buys1 sells

$1.51M total

M
4

Multiple Insiders

S - Sale+OE Insiders

0 buys20 sells

$1.00M total

G
5

Goldman Jonathan

Dir

0 buys1 sells

$163K total

Trading History
AVTX insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 16, 2026

2 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell39.9K$-12394.00$0

Sep 16, 2026

2 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell12.4K$16.33$202K

Sep 10, 2026

2 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell10.2K$17.62$179K

Sep 10, 2026

2 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell39.9K$-10185.00$0

Aug 28, 2026

2 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell51.8K$-679.00$0

Aug 28, 2026

2 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell679$20.00$14K

Aug 17, 2026

3 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell1.0K$20.00$20K

Aug 17, 2026

3 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell72.7K$19.94$1.45M

Aug 17, 2026

3 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell39.9K$-72725.00$0

Aug 10, 2026

3 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell679$20.00$14K

Aug 10, 2026

3 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell51.8K$-679.00$0

Aug 11, 2026

3 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell37.0K$-2655.00$0

Aug 11, 2026

3 months ago

Riley Jennifer

Chief Strategy Officer

C-Level
Sell2.7K$19.59$52K

Jul 27, 2026

3 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell1.0K$20.00$20K

Jul 27, 2026

3 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell51.8K$-1000.00$0

Jun 30, 2026

4 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell4.7K$20.00$93K

Jun 30, 2026

4 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell51.8K$-4654.00$0

Jun 23, 2026

5 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell51.8K$-1450.00$0

Jun 23, 2026

5 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell1.4K$18.00$26K

May 28, 2026

5 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell47.1K$-679.00$0

May 28, 2026

5 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell679$16.00$11K

May 15, 2026

6 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell3.6K$-3000.00$0

May 15, 2026

6 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell3.0K$18.76$56K

May 7, 2026

6 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell18.6K$24.12$449K

May 7, 2026

6 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell423$-18606.00$0

May 6, 2026

6 months ago

Varki Paul

GC

General Counsel
Sell75.1K$20.17$1.51M

May 5, 2026

6 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell3.6K$-108234.00$0

May 6, 2026

6 months ago

Chan Mitchell

Dir

Director
Sell3.2K$22.88$72K

May 6, 2026

6 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell3.6K$-75063.00$0

May 6, 2026

6 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell47.0K$20.19$949K

May 5, 2026

6 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell108.2K$20.61$2.23M

Apr 29, 2026

6 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell423$-16915.00$0

Apr 29, 2026

6 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell16.9K$13.16$223K

Apr 6, 2026

7 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell3.6K$-3970.00$0

Apr 6, 2026

7 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell4.0K$18.01$72K

Apr 1, 2026

7 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell679$16.00$11K

Apr 1, 2026

7 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell17.3K$-15959.00$0

Apr 1, 2026

7 months ago

Sullivan Christopher Ryan

CFO

CFO
Sell16.0K$16.96$271K

Mar 16, 2026

8 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell3.6K$-25492.00$0

Mar 16, 2026

8 months ago

Doyle Mittie

Chief Medical Officer

C-Level
Sell25.5K$16.15$412K

Nov 14, 2025

12 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell0$-11367.00$0

Nov 14, 2025

12 months ago

Goldman Jonathan

Dir

Director
Sell11.4K$14.33$163K

Nov 12, 2024

24 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell1.0K$1000.00$1.00M

Nov 12, 2024

24 months ago

Almenoff June Sherie

Dir

Director
Buy1.0K$12.75$13K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
AVTX Buy Conviction0%
Industry Rank#0 of 570
Volume Contribution0.1%
Total Industry Activity$16.52B

AVTX has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for AVTX

Over the last 90 days, corporate insiders at AVTX (AVTX) engaged in a total of 44 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 23 were sales. The total volume of insider trading reached $8.51M.

The net insider activity for AVTX shows a net selling bias of $8.49M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Doyle Mittie (Chief Medical Officer), who traded 108.2K shares valued at $2.23M on May 5, 2026.

Live Market News & Developments
Aggregated real-time headlines for AVTX (AVTX)
6 updates

Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX?

StockInvest.us3d ago

AVTX May 2027 15.000 call (AVTX270521C00015000) Stock Price, News, Quote & History

Yahoo! Finance Canada3d ago

AVTX - Avalo Therapeutics Inc Stock Price and Quote

Finviz177d ago

AVTX Forecast — Price Target — Prediction for 2027

TradingView147d ago

Price-Driven Insight from (AVTX) for Rule-Based Strategy

Stock Traders Daily3d ago

Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks

Yahoo Finance8d ago

FAQs About AVTX Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for AVTX.

Based on SEC Form 4 disclosures, the Insider Confidence Score for AVTX is currently 35/100, which reflects a moderate distribution bias. This calculation accounts for a total of 1 purchases and 23 sales by company executives over the last 90 days.

The CEO Conviction Index for AVTX is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.